Calcitriol and vitamin d analogs

Ana R. Jensen, Russell Z. Szmulewitz, Tomasz (Tom) Beer, Edwin M. Posadas

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Abstract

    Calcitriol (1,25-dihydroxycholecaliferol) is a synthetic analog of vitamin D that is physiologically active in absorption of calcium from the gastrointestinal tract. Recent clinical and laboratory developments have fueled enthusiasm for studying the role of vitamin D and its relationship to oncogenesis and malignant progression. There are epidemiological data pointing toward a link between vitamin D and prostate cancer as well as preclinical and clinical data linking antineoplastic activity of vitamin D receptor ligands with prostate cancer. As such, efforts have been geared toward the development of vitamin D receptor ligand-based therapy for early and advanced prostate cancer. In this chapter we will discuss the historic and current thoughts on the role that vitamin D may play in prostate cancer risk and treatment.

    Original languageEnglish (US)
    Title of host publicationDrug Management of Prostate Cancer
    PublisherSpringer New York
    Pages287-302
    Number of pages16
    ISBN (Print)9781603278317
    DOIs
    StatePublished - 2010

    Fingerprint

    Calcitriol
    Vitamin D
    Vitamins
    Prostatic Neoplasms
    Calcitriol Receptors
    Ligands
    Antineoplastic Agents
    Gastrointestinal Tract
    Carcinogenesis
    Calcium
    Therapeutics

    Keywords

    • Calcitriol
    • Vitamin D
    • Vitamin D receptor

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    Jensen, A. R., Szmulewitz, R. Z., Beer, T. T., & Posadas, E. M. (2010). Calcitriol and vitamin d analogs. In Drug Management of Prostate Cancer (pp. 287-302). Springer New York. https://doi.org/10.1007/978-1-60327-829-4_26

    Calcitriol and vitamin d analogs. / Jensen, Ana R.; Szmulewitz, Russell Z.; Beer, Tomasz (Tom); Posadas, Edwin M.

    Drug Management of Prostate Cancer. Springer New York, 2010. p. 287-302.

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Jensen, AR, Szmulewitz, RZ, Beer, TT & Posadas, EM 2010, Calcitriol and vitamin d analogs. in Drug Management of Prostate Cancer. Springer New York, pp. 287-302. https://doi.org/10.1007/978-1-60327-829-4_26
    Jensen AR, Szmulewitz RZ, Beer TT, Posadas EM. Calcitriol and vitamin d analogs. In Drug Management of Prostate Cancer. Springer New York. 2010. p. 287-302 https://doi.org/10.1007/978-1-60327-829-4_26
    Jensen, Ana R. ; Szmulewitz, Russell Z. ; Beer, Tomasz (Tom) ; Posadas, Edwin M. / Calcitriol and vitamin d analogs. Drug Management of Prostate Cancer. Springer New York, 2010. pp. 287-302
    @inbook{23e9913e371f456282717d88f347fd34,
    title = "Calcitriol and vitamin d analogs",
    abstract = "Calcitriol (1,25-dihydroxycholecaliferol) is a synthetic analog of vitamin D that is physiologically active in absorption of calcium from the gastrointestinal tract. Recent clinical and laboratory developments have fueled enthusiasm for studying the role of vitamin D and its relationship to oncogenesis and malignant progression. There are epidemiological data pointing toward a link between vitamin D and prostate cancer as well as preclinical and clinical data linking antineoplastic activity of vitamin D receptor ligands with prostate cancer. As such, efforts have been geared toward the development of vitamin D receptor ligand-based therapy for early and advanced prostate cancer. In this chapter we will discuss the historic and current thoughts on the role that vitamin D may play in prostate cancer risk and treatment.",
    keywords = "Calcitriol, Vitamin D, Vitamin D receptor",
    author = "Jensen, {Ana R.} and Szmulewitz, {Russell Z.} and Beer, {Tomasz (Tom)} and Posadas, {Edwin M.}",
    year = "2010",
    doi = "10.1007/978-1-60327-829-4_26",
    language = "English (US)",
    isbn = "9781603278317",
    pages = "287--302",
    booktitle = "Drug Management of Prostate Cancer",
    publisher = "Springer New York",

    }

    TY - CHAP

    T1 - Calcitriol and vitamin d analogs

    AU - Jensen, Ana R.

    AU - Szmulewitz, Russell Z.

    AU - Beer, Tomasz (Tom)

    AU - Posadas, Edwin M.

    PY - 2010

    Y1 - 2010

    N2 - Calcitriol (1,25-dihydroxycholecaliferol) is a synthetic analog of vitamin D that is physiologically active in absorption of calcium from the gastrointestinal tract. Recent clinical and laboratory developments have fueled enthusiasm for studying the role of vitamin D and its relationship to oncogenesis and malignant progression. There are epidemiological data pointing toward a link between vitamin D and prostate cancer as well as preclinical and clinical data linking antineoplastic activity of vitamin D receptor ligands with prostate cancer. As such, efforts have been geared toward the development of vitamin D receptor ligand-based therapy for early and advanced prostate cancer. In this chapter we will discuss the historic and current thoughts on the role that vitamin D may play in prostate cancer risk and treatment.

    AB - Calcitriol (1,25-dihydroxycholecaliferol) is a synthetic analog of vitamin D that is physiologically active in absorption of calcium from the gastrointestinal tract. Recent clinical and laboratory developments have fueled enthusiasm for studying the role of vitamin D and its relationship to oncogenesis and malignant progression. There are epidemiological data pointing toward a link between vitamin D and prostate cancer as well as preclinical and clinical data linking antineoplastic activity of vitamin D receptor ligands with prostate cancer. As such, efforts have been geared toward the development of vitamin D receptor ligand-based therapy for early and advanced prostate cancer. In this chapter we will discuss the historic and current thoughts on the role that vitamin D may play in prostate cancer risk and treatment.

    KW - Calcitriol

    KW - Vitamin D

    KW - Vitamin D receptor

    UR - http://www.scopus.com/inward/record.url?scp=84891398689&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84891398689&partnerID=8YFLogxK

    U2 - 10.1007/978-1-60327-829-4_26

    DO - 10.1007/978-1-60327-829-4_26

    M3 - Chapter

    AN - SCOPUS:84891398689

    SN - 9781603278317

    SP - 287

    EP - 302

    BT - Drug Management of Prostate Cancer

    PB - Springer New York

    ER -